p. 1−16
2676-5861
Vol.37/No.1
p. 17−21
2676-5861
Vol.37/No.1
p. 23−29
2676-5861
Vol.37/No.1
p. 30−41
2676-5861
Vol.37/No.1
p. 42−51
2676-5861
Vol.37/No.1
97%). The biodistribution of 153Sm and 153Sm-zoledronate performed in 2-48 h and for 175Yb and the 175Yb-zoledronate performed in 2-96 h post injection in the Syrian mice. The maximum bone uptake for 153Sm-zoledronate was 4% (48 h), while for 175Yb-zoledronate it was 10% (48 h). The complexes demonstrated satisfactory stability in the presence of human serum and the final formulations. However, the complexes are not appropriate for human studies due to the high liver uptake, possibly due to release of free metal from the complex and/or colloid formation.]]>
p. 52−61
2676-5861
Vol.37/No.1
p. 62−71
2676-5861
Vol.37/No.1
p. 72−79
2676-5861
Vol.37/No.1
p. 80−86
2676-5861
Vol.37/No.1
p. 87−99
2676-5861
Vol.37/No.1